rociletinib: Clinical Trials

5 terminated, 1 no longer available, 1 withdrawn. 5 Phase 2, 3 Phase 1, 1 Phase 3.

By phase and status

Phase	Trials	Status
Phase 2	5	Terminated 4, Withdrawn 1
Phase 1	3	Terminated 3
Phase 3	1	Terminated 1

Follow rociletinib: new trials by email Literature Review of rociletinib trials Research Report on rociletinib

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Rociletinib Genomic Landscape in Non-small Cell Lung Cancer (NSCLC) Rociletinib, Biopsy, Blood draw - Carcinoma, Non-Small-Cell Lung, Non-Small Cell Lung Cancer	Phase 2	Withdrawn	Washington University School of Medicine		2016-05-01	2016-05-17
A Phase 1b/2 Study of Safety and Efficacy of Rociletinib in Combination With MPDL3280A in Patients With Advanced or Metastatic EGFR-mutant NSCLC Rociletinib, MPDL3280A - Non-small Cell Lung Cancer	Phase 1 / Phase 2	Terminated	Clovis Oncology, Inc.	3	2016-02-24	2019-07-05
Phase 1/2 Study of the Safety and Efficacy of Rociletinib in Combination With Trametinib in Patients With mEGFR-positive Advanced or Metastatic Non-small Cell Lung Cancer Rociletinib, Trametinib - Non-small Cell Lung Cancer	Phase 1 / Phase 2	Terminated	Clovis Oncology, Inc.	7	2015-09-30	2018-10-02
TIGER-3: Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy Rociletinib, Pemetrexed or gemcitabine or paclitaxel or docetaxel - Non-small Cell Lung Cancer	Phase 3	Terminated	Clovis Oncology, Inc.	149	2015-02-01	2019-08-14
Multicenter Study of Rociletinib Administered to Patients With Previously Treated Mutant EGFR Non-small Cell Lung Cancer Rociletinib - Non-small Cell Lung Cancer	Phase 2	Terminated	Clovis Oncology, Inc.	318	2014-06-16	2020-08-12
Study to Evaluate Safety, Pharmacokinetics, and Efficacy of Rociletinib (CO-1686) in Previously Treated Mutant Epidermal Growth Factor Receptor (EGFR) in Non-Small Cell Lung Cancer (NSCLC) Patients Rociletinib - Locally Advanced or Metastatic Non Small Cell Lung Cancer	Phase 1 / Phase 2	Terminated	Clovis Oncology, Inc.	612	2012-03-27	2020-08-04
Rociletinib (CO-1686) USA Expanded Access Program Rociletinib - Non-small Cell Lung Cancer		No longer available	Clovis Oncology, Inc.			2018-09-25

Conditions studied

Carcinoma, Non-Small-Cell Lung (7)  ·  Neoplasm Metastasis (3)  ·  Neoplasms (3)  ·  Recurrence (3)

Sponsors

Clovis Oncology, Inc. (6)  ·  Washington University School of Medicine (1)

Countries

United States (6)  ·  Australia (3)  ·  France (3)  ·  Germany (2)  ·  Netherlands (2)  ·  South Korea (2)  ·  Spain (2)  ·  Taiwan (2)  ·  United Kingdom (2)  ·  Canada (1)  ·  Hong Kong (1)  ·  Italy (1)  ·  Poland (1)  ·  Switzerland (1)

Top investigators

Lindsey Rolfe, MD (1)  ·  Paula O'Connor, MD (1)  ·  Saiama Waqar, M.D. (1)

Results publications

PMID 25923550, PMID 29216356